PA200通过差异调节蛋白酶体,并抑制NSCLC细胞的迁移

Ayse S Yazgili1, Georgia A Giotopoulou1, Sabine J Behrend1

  • 1Comprehensive Pneumology Center (CPC), University Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Max-Lebsche Platz 31, 81377 Munich, Germany.

PubMed
概括

蛋白质酶激活剂200 (PA200) 驱动肺癌细胞的入侵和转移. 它的删除会影响细胞特异性蛋白酶体功能,影响癌症的扩散和非小细胞肺癌 (NSCLC) 的不良预后.